Medical specialties

Arix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL

Friday, September 18, 2020 - 9:00am

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

Key Points: 
  • Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
  • "Today we presented data from our recommended Phase 2 dose cohort from the ALEXANDER trial of AUTO3, a CD19 and CD22 dual targeting CAR T product candidate in DLBCL.
  • The data support a best in class profile with a high level of complete remissions and a well tolerated safety profile," said Dr.Christian Itin, chairman and chief executive officer of Autolus.
  • As of the data cut-off date of August 3, 2020, 35 patients in the ALEXANDER Phase 1/2 clinical trial of AUTO3 have been treated and were evaluable for safety.

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020

Friday, September 18, 2020 - 8:05am

Today we presented data from our recommended Phase 2 dose cohort from the ALEXANDER trial of AUTO3, a CD19 and CD22 dual targeting CAR T product candidate in DLBCL.

Key Points: 
  • Today we presented data from our recommended Phase 2 dose cohort from the ALEXANDER trial of AUTO3, a CD19 and CD22 dual targeting CAR T product candidate in DLBCL.
  • As of the data cut-off date of August 3, 2020, 35 patients in the ALEXANDER Phase 1/2 clinical trial of AUTO3 have been treated and were evaluable for safety.
  • AUTO3 was well tolerated, with no Grade 3 or higher cytokine release syndrome (CRS) with primary infusion and low rates of neurotoxicity (NT).
  • In terms of efficacy data, of the 35 patients dosed to date, 30 patients were evaluable within their completed cohort.

Global Biliary Atresia Market Insights, Epidemiology and Forecasts, 2017-2019 & 2020-2030

Thursday, September 17, 2020 - 10:45pm

Biliary Atresia - Market Insights, Epidemiology and Forecast to 2030 delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • Biliary Atresia - Market Insights, Epidemiology and Forecast to 2030 delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Biliary Atresia market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Biliary Atresia market size from 2017 to 2030 segmented by seven major markets.
  • The market size of Biliary Atresia in the seven major markets was found to be USD 2.9 million, in 2017.
  • We perform Competitive & Market Intelligence analysis of the Biliary Atresia Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc.

Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

Thursday, September 17, 2020 - 9:07pm

Preclinical data has demonstrated that modulating the CD6-ALCAM pathway has the potential to inhibit the activation and trafficking of both Th2 and Th17 effector T cells.

Key Points: 
  • Preclinical data has demonstrated that modulating the CD6-ALCAM pathway has the potential to inhibit the activation and trafficking of both Th2 and Th17 effector T cells.
  • Therefore, Equillium is evaluating itolizumab in uncontrolled moderate to severe asthma, regardless of eosinophilia level, to assess the breadth of its clinical utility.
  • The EQUIP study is a Phase 1b randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of itolizumab in patients with uncontrolled moderate-to-severe asthma ( NCT04007198 ).
  • Equilliums initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Thursday, September 17, 2020 - 9:01pm

MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.

Key Points: 
  • MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.
  • The Phase 1b portion is an open-label dose escalation study which is evaluating doses up to 75 mg of KZR-616 across 6 cohorts, which has completed enrollment.
  • The Phase 2 portion of the MISSION study evaluating KZR-616 in patients with LN is currently enrolling.
  • Data generated from Phase 1a and 1b trials provide evidence that KZR-616 exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.

AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020

Thursday, September 17, 2020 - 9:01pm

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2021 before the market open on Tuesday, September 29, 2020.

Key Points: 
  • AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2021 before the market open on Tuesday, September 29, 2020.
  • To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13710506.
  • This conference call will also be webcast and can be accessed from the Investors section of the AngioDynamics website at www.angiodynamics.com .
  • AngioDynamics diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.

Food Equality Initiative, FEI presents For the Health™: A Conversation on Race & Food Allergy, featuring a panel of food Industry Experts

Thursday, September 17, 2020 - 8:45pm

Emily Brown says this, "For the Health webinar series is creating a dialogue on racial and economic disparities in food allergy.

Key Points: 
  • Emily Brown says this, "For the Health webinar series is creating a dialogue on racial and economic disparities in food allergy.
  • It is my hope that words will move to action, and we will see real lasting change."
  • Research shows that Black children are 7% more likely to have food allergies compared to white children, are diagnosed less frequently, receive less medical care, and are more likely to experience anaphylaxis.
  • Learn more about this and how you can help at Food Equality Initiative .

United Spinal Plays Key Role In Passage Of Resolution Designating September 2020 As Spinal Cord Injury Awareness Month

Thursday, September 17, 2020 - 8:44pm

NEW YORK, Sept. 17, 2020 /PRNewswire/ -- United Spinal Association was instrumental in championing a resolution that passed the U.S. Senate designating September 2020 as National Spinal Cord Injury Awareness Month.

Key Points: 
  • NEW YORK, Sept. 17, 2020 /PRNewswire/ -- United Spinal Association was instrumental in championing a resolution that passed the U.S. Senate designating September 2020 as National Spinal Cord Injury Awareness Month.
  • We are grateful for their support," said James Weisman, president and CEO of United Spinal Association.
  • "United Spinal looks forward to working with both senators and all of Congress to address the issues impacting our community," added Weisman.
  • People who sustain a spinal cord injury often have permanent and profound neurologic deficits and accompanying disability.

Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications

Thursday, September 17, 2020 - 8:10pm

NASHVILLE, Tenn., Sept. 17, 2020 /PRNewswire/ -- Amytrx Therapeutics, Inc., ("Amytrx"), a clinical stage biopharmaceutical company advancing next-generation inflammation-targeting therapies, today launched from stealth to announce the company's novel therapeutic platform, clinical development plans, and preclinical program initiatives.

Key Points: 
  • NASHVILLE, Tenn., Sept. 17, 2020 /PRNewswire/ -- Amytrx Therapeutics, Inc., ("Amytrx"), a clinical stage biopharmaceutical company advancing next-generation inflammation-targeting therapies, today launched from stealth to announce the company's novel therapeutic platform, clinical development plans, and preclinical program initiatives.
  • Founded in 2014, Nashville-based Amytrx is developing AMTX-100, a new anti-inflammatory therapeutic platform, which has broad potential in multiple inflammatory, autoimmune, and metabolic diseases.
  • Post-licensing, Amytrx secured $11 million in Series A financing from prominent investors to advance a pipeline of best-in-class anti-inflammatory therapies for diseases with significant unmet medical need.
  • Amytrx has achieved several important milestones in early 2020, advancing a potentially best-in-class topical formulation of AMTX-100 into clinical development for dermatologic indications.

Is it COVID, the Flu or Something Far Deadlier? Patient Safety Authority warns "Don't miss sepsis"

Thursday, September 17, 2020 - 7:32pm

HARRISBURG, Pa., Sept. 17, 2020 /PRNewswire/ -- With a combined COVID-19/ flu season approaching, the Patient Safety Authority (PSA) is warning Pennsylvanians about another, even deadlier condition.

Key Points: 
  • HARRISBURG, Pa., Sept. 17, 2020 /PRNewswire/ -- With a combined COVID-19/ flu season approaching, the Patient Safety Authority (PSA) is warning Pennsylvanians about another, even deadlier condition.
  • Symptoms such as fever, shortness of breath, and fatigue often mimic those of COVID-19 and the flu.
  • In 2017, sepsis took the lives of more than 2,400 Pennsylvanians, including babies, children, and healthy adults.
  • "September is Sepsis Awareness Month, so we are asking everyone to heed the advice of our campaign: Don't miss sepsis.